Table 1

Echocardiographic measurements in doxorubicin-treated mice

Measurements shown are matched from 6–9 days after injection. Cbr1 +/− mice are different from +/+ mice and equivalent to untreated controls at a statistically significant level for all manifestations (P < 0.002). Mean values ± SE are shown. Cbr1 +/− mice were still equivalent to controls at 15 days after injection (P < 0.004) after most +/+ mice had died. Untreated control data include combined data from both genotypes. LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; IVSD, interventricular septal wall thickness at end diastole; LVPWTD, left ventricular posterior wall thickness at end diastole; FS, fractional shortening; EF, ejection fraction; HR, heart rate.

Cbr1 +/+ (n = 7)Cbr1 +/− (n = 8)Untreated (n = 8)
LVEDD (mm)3.40 ± 0.102.74 ± 0.082.96 ± 0.03
LVESD (mm)2.06 ± 0.161.07 ± 0.081.03 ± 0.01
IVSD (mm)0.55 ± 0.070.76 ± 0.060.86 ± 0.01
LVPWTD (mm)0.51 ± 0.050.78 ± 0.060.86 ± 0.01
FS (%)39.7 ± 3.860.6 ± 3.465.2 ± 0.2
EF (%)62.9 ± 4.083.9 ± 3.287.9 ± 0.1
HR (beats/min)343 ± 61649 ± 16656 ± 3